Richter also markets as part of its portfolio original products and continues to carry out intensive research activities on diseases of the Central Nervous System. It is management’s opinion that it is important for the longer term success of the Group that it continues to research own developed compounds.

Gedeon Richter is a regional mid-sized pharma company with a vertically integrated structure. This is based on a good market position with geographic and therapeutic niches supported by continuous enhancement through the supply of specialties partly via licensing agreements. Licensing-in is becoming an increasingly important route for the Group to renew its product portfolio. This is accomplished partly as an expansion of our existing generic product line and partly via providing high added value products either in the field of female healthcare or with original features in other therapeutic areas.

Richter’s management continues to endeavour to provide greater focus and improved shape to the product portfolio. With this background it is understandable that most of the top ten products in 2009 originate from the three largest therapeutic categories. Gynaecological, cardiovascular and central nervous system products together generated 71 percent of total pharmaceutical sales.  

Gynaecological products